SWTX SpringWorks Therapeutics, Inc. Insider Trading

COO Edris Badreddin sells 20,000 SWTX shares across 4 transactions for $1,084,592.24; stock up 41.2% in 30 days but down 15.6% from 52-week high.

Edris Badreddin, Chief Operating Officer, executed 4 separate sales totaling 20,000 shares (20.0K shares) for $1,084,592.24 at a blended average price of $54.23 on 2025-03-03, reducing his holdings by 10.5% to 169.7K shares. The timing is contextually mixed: the stock has rallied 41.2% over the prior 30 days and 21.2% over the prior 90 days, yet remains 15.6% below its 52-week high of $59.93. Within the same ticker (SWTX), his prior 4 measurable sells (excluding a recent 2025-02-10 sale) showed 0 well-timed outcomes at the 90-day mark—all four resulted in positive 90-day returns after the sale, meaning the stock rose post-sale. Company fundamentals show rapid revenue growth of 3417.3% year-over-year, but the business remains unprofitable with a net loss of $-53,530,000.00 against quarterly revenue of $49,301,000.00. The magnitude and frequency of this insider's sales merit observation, though the pattern does not yet suggest prescience about future stock direction.

CEO Islam Saqib sold 49,000 shares (4.9% of holdings) for $2.7M across 5 transactions on 2025-03-03

Islam Saqib, Chief Executive Officer of SpringWorks Therapeutics, executed 5 separate sales totaling 49,000 shares for $2,657,655.82 on 2025-03-03, reducing his holdings from 1,003,869 to 954,869 shares. The blended average sale price was $54.24, which is notably above the current price of $50.59 (the stock has declined 15.6% from its 52-week high of $59.93). Across his cross-ticker open-market history, Saqib's 13 prior sells have achieved a 22.22% well-timed rate (where negative 90-day returns indicate the insider sold before declines), yet his average 90-day return after sells was +10.2%, meaning those transactions were generally poorly timed as the stock rose afterward. At SWTX specifically, his prior 5 trades show only 1 measurable outcome (the 2024-12-02 sell), which was poorly timed (+39.7% 90-day return). The company faces significant headwinds: net income of $-53,530,000.00 against revenue of $49,301,000.00 in the latest quarter, with the company unprofitable over its most recent full fiscal year. The 30-day price momentum (+41.2%) contrasts sharply with the cross-ticker track record's average 30-day return after his sells (-14.3%), and the recent concentration of his SWTX sales (four trades in February 2025 alone) alongside this substantial March sale warrants observation of whether this pattern reflects a systematic reduction in CEO exposure.

Director Lynch sold 47,600 shares (47.6K) for $2,866,534.08 at $60.22 avg, reducing stake 36.5%

Daniel Lynch, a director at SpringWorks Therapeutics, executed 2 separate sales on 2025-02-20, totaling 47,600 shares for $2,866,534.08 at a blended average price of $60.22. The sale reduced his holdings by 36.5%, from 130,544 shares to 82,944 shares. The transaction occurred just 10 days after Lynch's prior three sales on 2025-02-10 at the same ticker. SpringWorks remains unprofitable with a quarterly net income of $-53,530,000.00 despite strong recent revenue growth of +3417.3% year-over-year. The current stock price of $56.56 is -5.6% from the 52-week high and the sales were executed near the top of the recent 52-week range ($28.61–$59.93), reflecting prices above current levels. Investors should note the concentrated selling activity within a 10-day window and the substantial reduction in this director's ownership stake in a pre-profitable biotech company.

CEO Islam Saqib sold 29.3K SWTX shares for $1.8M (blended avg $60.30) on 2025-02-20, reducing holdings 2.8%

Islam Saqib, CEO of SpringWorks Therapeutics, executed 2 separate sales totaling 29,328 shares for $1,768,400.79 on 2025-02-20. The blended average price of $60.30 compares to the current market price of $56.56, meaning the shares have declined 5.6% from the 52-week high of $59.93. At the same-ticker level, Saqib's 5 prior trades show poor timing: only 1 of these prior sales has a 90-day outcome measurable, which was positive—indicating the stock rose after he sold (poorly-timed). His cross-ticker track record shows an average 90-day return of +2.0% following 11 prior sells, with just 28.57% of those characterized as well-timed. The company generated $49.3M revenue in the latest quarter but reported a net loss of $-53.5M, highlighting material unprofitability despite 3417.3% annual revenue growth and a $4.2B market capitalization. The recent sales follow earlier sells on 2025-02-14 and 2025-02-10, showing a cluster of dispositions within days.

CEO Islam Saqib sold 10,672 shares of SWTX at $59.92 on 2025-02-14 ($639.5K); stock now $55.73.

CEO Islam Saqib sold 10,672 shares at $59.92, reducing holdings from 1,074,625 to 1,063,953 shares—a -1.0% portfolio reduction. The sale occurred near the 52-week peak ($59.28), with the stock subsequently declining 6.0% to the current $55.73. Across his prior 5 trades at SWTX, Saqib's sells have not demonstrated reliable timing: 0 of 2 measurable 90-day outcomes showed positive returns (well-timed), with 90-day returns of +1.9% and +4.4% on earlier September sales—indicating the stock typically recovered post-sale. Against that pattern, this February sale at the intra-quarter peak warrants investor attention, particularly given the company's unprofitability ($-53.5M net income in the latest full fiscal year) and the recent 30-day surge (+60.9%) that preceded the sale.

CEO Islam Saqib sold 48,000 shares at $53.30 on 2025-02-10; stock now at $59.28, up 60.2% in 30 days post-trade.

Islam Saqib, as CEO, sold 48,000 shares (4.6% of pre-transaction holdings) at $53.30, reducing his stake from 1,050,502 to 1,002,502 shares. The stock has since appreciated $59.28, representing a +60.2% gain in the 30 days following the sale. This contrasts sharply with his prior same-ticker history at SWTX: across 5 recent sales (all in 2024), 4 generated negative 30-day returns ranging from -12.6% to -24.4%, with only 1 of 3 measurable 90-day outcomes being well-timed (negative return). In this case, the sale occurred near the 52-week high of $59.28, yet the stock rallied significantly afterward—marking a poorly-timed exit relative to near-term price action. Against the backdrop of ongoing unprofitability (net income of $-53,530,000.00 in the latest quarter), the CEO's sale patterns merit close observation for whether they signal operational or strategic shifts rather than mere portfolio activity.

Director Lynch sells 175,000 shares (57.2% of holdings) for $9.5M across 3 transactions; stock up 60.2% in 30 days

Director Daniel Lynch sold 175,000 shares in three separate transactions at prices ranging from $53.23 to $55.51, reducing his stake from 305,944 shares to 130,944 shares. The magnitude is substantial: this represents a 57.2% reduction in his holdings and $9,530,351.22 in proceeds. The timing context is noteworthy—the stock has appreciated 60.2% over the past 30 days and 62.2% over the past 90 days, trading at its 52-week high of $59.28. Lynch's blended sale price of $54.46 sits below the current price, indicating the sales occurred earlier in or concurrent with the recent rally. Against this backdrop, the company remains unprofitable, with the latest quarter showing net income of $-53,530,000.00 despite revenues of $49,301,000.00. The large percentage reduction in holdings by a director during a strong uptrend, combined with the company's negative profitability metrics, merits attention to understand the rationale.

SpringWorks COO sold 30.0K shares at $53.13; stock now at $59.28 (+0.0% from 52-week high); company unprofitable.

Edris Badreddin, SpringWorks Chief Operating Officer, sold 30,000 shares on 2025-02-10 at $53.13 per share, reducing holdings by 13.7% from 219.7K to 189.7K shares. The sale occurred at $5.98 below the current price of $59.28, which stands at the 52-week high. At SpringWorks, his prior sell track record shows a mixed record: three sales on 2024-09-03 realized 90-day declines of -20.6%, -22.6%, and -24.4%, while two December 2024 sales have measurable 30-day returns of -13.6% and -14.6%. The company remains unprofitable with $-53.5M net income on $49.3M quarterly revenue, despite a $4.4B market cap. The divergence between the transaction price and current market price, combined with his uneven timing history at this ticker, warrants investor attention to whether this sale foreshadows near-term weakness or represents a discrete liquidity event.

CPO Daniel Pichl sells 29,750 shares at $54.36 avg; 100% of his prior SWTX sales were well-timed (stock fell post-trade).

Daniel Pichl, Chief People Officer, executed 3 separate sales totaling 29,750 shares for $1,617,329.10 on 2025-02-10, reducing his holdings by 37.0% to 50,762 shares post-transaction. The sales occurred at an average price of $54.36, below the current price of $59.28. Remarkably, all 5 of Pichl's prior open-market sales at SWTX were well-timed, with negative 90-day returns following each sale—a 100% timing pattern at this ticker. His cross-ticker track record shows a 90-day well-timed rate of 100.00%, indicating consistent ability to sell before subsequent declines. Against this backdrop, the stock is at its 52-week high ($59.28) and has surged +60.2% over the last 30 days and +62.2% over 90 days—a sharp ascent that raises the question whether the insider's historical sell-timing edge may translate to this current transaction, especially given that the company remains unprofitable with a net income of $-53,530,000.00 in the latest quarter.

COO Edris Badreddin sold 20,000 shares at $41.97 avg; holds 209.6K shares post-sale at unprofitable biotech.

Edris Badreddin, COO of SpringWorks Therapeutics, executed 2 separate sales totaling 20,000 shares on 2024-12-03 for $839,335.79 at a blended average price of $41.97, reducing his holdings by 8.7% to 209.6K shares. The current price of $41.75 is 20.5% below the 52-week high of $52.50, and the stock has risen +32.2% in the past 30 days following a recent sell pattern: his prior 5 trades at SWTX (all sells in June and September 2024) showed mixed 90-day outcomes, with only 40% well-timed on the 90-day horizon. His cross-ticker track record of 7 prior sells shows an average 90-day return of +2.0%, indicating the stock typically rose after his sales—a pattern of poorly-timed exits. The sale occurs at a company with quarterly revenue of $49.3M but a negative net income of $-53.5M, reflecting unprofitability in the most recent full fiscal year.